Viking Therapeutics surges after presenting ‘promising’ obesity drug data
The Fly

Viking Therapeutics surges after presenting ‘promising’ obesity drug data

Viking Therapeutics (VKTX) presented at the ObesityWeek meeting on Sunday, noting “promising” early results for its experimental obesity pill, with increased weight loss at higher doses, IBD’s Ed Carson reports. Patients taking 100-miligram doses of Viking’s VK2735 lost 8.2% of their body weight after 28 days, or 6.8% more than those taking a placebo, and no patients taking the highest dose stopped taking it, according to the report. Other companies that make weight-loss drugs include Eli Lilly (LLY) and Novi Nordisk (NVO). Shares of Viking Therapeutics were up nearly 25% in premarket trading.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App